Results of Extended and Combined Surgical Methods for Advanced Stomach Cancer
Keywords:
stomach cancer, locally widespread, combined operations, palliative gastrectomyAbstract
In the study, pancreatic involvement was observed in 91.2% of cases in T4 gastric cancer. Moreover, with the same frequency (34.5%), ingrowth into the pancreas was combined with damage to the transverse colon and around vessels. The prognostic factors that determine the survival of patients with T4 gastric cancer remain unclear. Data on the immediate results of combined operations performed for locally pervasive gastric cancer vary considerably in the literature. The frequency of postoperative complications ranges from 5 to 59.4%, postoperative mortality - from 3.3 to 24.2%. The optimal surgical tactics for the treatment of patients with locally widespread gastric cancer has not been determined. Not only the indications for combined resections and palliative interventions remain controversial, but also the immediate and long-term results of treatment, which determines the relevance of continuing research.
References
1. Бесова Н. С. и др. Рак желудка // Современная онкология. - 2021. - Т. 23. -№. 4. - С. 541-571.
2. Бесова Н. С. и др. Практические рекомендации по лекарственному лечению рака желудка // Злокачественные опухоли. - 2022. - Т. 12. - №. 3S2-1. - С. 382-400.
3. Под ред. Каприна А. Д., Старинского В. В., Шахзадовой А. О. Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России. - 2022.
4. Aleksander S. A. et al. The Gene Ontology knowledgebase in 2023 // Genetics. -2023. - Т. 224. - №. 1. - С. iyad031.
5. Chandramohan V. et al. Validation of an immunohistochemistry assay for detection of CD155, the poliovirus receptor, in malignant gliomas // Archives of pathology & laboratory medicine. - 2017. - T. 141. - №. 12. - C. 1697-1704.
6. Chocarro L. et al. Understanding LAG-3 signaling // International journal of molecular sciences. - 2021. - T. 22. - №. 10. - C. 5282.
7. Chou F. C. et al. Role of galectins in tumors and in clinical immunotherapy // International journal of molecular sciences. - 2018. - T. 19. - №. 2. - C. 430. T. 10. - №. 5. - C. 750.
8. Dankner M. et al. CEACAM1 as a multi-purpose target for cancer immunotherapy // Oncoimmunology. - 2017. - T. 6. - №. 7. - C. e1328336. 2014. - T. 92. - №. 3. - C. 237-244.
9. Gu L. et al. PD-L1 and gastric cancer prognosis: A systematic review and metaanalysis // PloS one. - 2017. - T. 12. - №. 8. - C. e0182692.
10. Han Z. W. et al. The old CEACAMs find their new role in tumor immunotherapy // Investigational New Drugs. - 2020. - T. 38. - C. 1888-1898.
11. Hemminki A. et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome // Nature. - 1998. - T. 391. - №. 6663. - C. 184-187.
12. Huang Y. H. et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion // Nature. - 2015. - T. 517. - №. 7534. - C. 386-390.
13. Kavun A. et al. Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor Therapy // Cancers. - 2023. -T. 15. - №. 8. - C. 2288.
14. Keir M. E. et al. PD-1 and its ligands in tolerance and immunity // Annu. Rev. Immunol. - 2008. - T. 26. - № 1. - C. 677-704.
15. Latchman Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation // Nature immunology. - 2001. - T. 2. - №. 3. - C. 261-268.
16. Li X. Y. et al. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms // The Journal of clinical investigation. - 2018. - T. 128. - №. 6. - C. 2613-2625.
17. Liu H. et al. Association between high galectin expression and poor prognosis in hematologic cancers: a systematic review and meta-analysis // Hematology. -2023. - Т. 28. - №. 1. - С. 2227494.
18. Loo D. et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity // Clinical cancer research. - 2012. - Т. 18. - №. 14. С. 3834-3845.
19. Luo C. et al. A poliovirus receptor (CD155)-Related risk signature predicts the prognosis of bladder cancer // Frontiers in Oncology. - 2021. - T. 11. - C. 660273.
20. Ma W. et al. Targeting immunotherapy for bladder cancer by using anti-CD3x CD155 bispecific antibody //Journal of Cancer. - 2019. - T. 10. - №. 21. - C. 5153-5161.
21. Molfetta R. et al. CD155: A multi-functional molecule in tumor progression // International journal of molecular sciences. - 2020. - T. 21. - №. 3. - C. 922.
22. Morais S. et al. Salt intake and gastric cancer: a pooled analysis within the Stomach cancer Pooling (StoP) Project // Cancer Causes & Control. - 2022. - T. 33. - №. 5. - C. 779-791.
23. Nakahara S., Raz A. Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway // Cancer and Metastasis Reviews. - 2007. - T. 26. - № 3-4. - C. 605-610.
24. Ni P. et al. Prognostic significance of ADAM17 for gastric cancer survival: a metaanalysis // Medicina. - 2020. - T. 56. - №. 7. - C. 322.
25. Okada K. et al. Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer // Anticancer research. - 2006. - T. 26. - №. 2B. - C. 1369-1376.
26. Öztürk S. et al. IDO1-Targeted therapy does not control Disease Development in the E^-TCL1 mouse model of chronic lymphocytic leukemia // Cancers. - 2021. -T. 13. - №. 8. - C. 1899.
27. Parkin D. M. International variation // Oncogene. - 2004. - T. 23. - №. 38. - C. 6329-6340.
28. Parsonnet J. et al. Helicobacter pylori infection in intestinal-and diffuse-type gastric adenocarcinomas // JNCI: Journal of the National Cancer Institute. - 1991. T. 83. - №. 9. - C. 640-643.
29. Patel S. P., Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy // Molecular cancer therapeutics. - 2015. - T. 14. - №2. 4. - C. 847856.
30. Peyraud F. et al. Targeting tryptophan catabolism in cancer immunotherapy era: challenges and perspectives // Frontiers in Immunology. - 2022. - T. 13. - C. 807271.
31. Pham Q. T. et al. Essential roles of TDO2 in gastric cancer: TDO2 is associated with cancer progression, patient survival, PD-L1 expression, and cancer stem cells // Pathobiology. - 2023. - T. 90. - №. 1. - C. 44-55.
32. Prendergast G. C. et al. Indoleamine 2, 3-dioxygenase and its therapeutic inhibition in cancer // International review of cell and molecular biology. - 2018. - T. 336. -C. 175-203.
33. Saad M. I., Rose-John S., Jenkins B. J. ADAM17: an emerging therapeutic target for lung cancer // Cancers. - 2019. - T. 11. - №. 9. - C. 1218.
34. Shenderov E. et al. Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate-and high-risk prostate cancer // J. Clin. Oncol. - 2018. - T. 36. - C. 15.
35. Wang C. et al. Galectin-3 may serve as a marker for poor prognosis in colorectal cancer: A meta-analysis // Pathology-Research and Practice. - 2019. - T. 215. -№. 10. - C. 152612.
36. Wang J. B. et al. An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer // Nature Communications. 2020a. - T. 11. - №. 1. - C. 6352.
37. Yong H. et al. CD155 expression and its prognostic value in postoperative patients with breast cancer // Biomedicine & pharmacotherapy. - 2019. - T. 115. - C. 108884.
38. Zhang Q. et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity // Nature immunology. - 2018. - T. 19. - №. 7. - C. 723-732.
39. Kuliev A.A., Juraev M.D. и др. // Turkish Journal of Physiotherapy and Rehabilitation; 32(3) 2021. C 7242-7245
40. Кулиев А.А., Джураев М.Д. и др. // Academic research in educational sciences scientific journal 2021. №2. C 291-307
41. Кулиев А.А., Джураев М.Д. и др. // Журнал биомедицины и практики; №2 2021. C 132-138.
42. Kuliev A.A., Juraev M.D. и др. // The American Journal of Medical Sciences and Pharmaceutical Research (ISSN – 2689-1026) 2023. C 70-77.
